| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于通过药品 GMP 符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）收到浙 江省药品监督管理局签发的《药品GMP符合性检查告知书》（浙2025第0267号、浙 2025第0268号），现将相关情况公告如下： 一、GMP 检查相关信息 企业名称：奥锐特药业股份有限公司 生产地址：浙江省天台县八都工业园区 检查范围及相关车间、生产线：1.原料药（糠酸莫米松）：806、863车间， A3生产线；2.原料药（倍他米松）：802车间，BETB生产线 检查时间：2025年11月12日-2025年11月14日 检查结论：符合《中华人民共和国药品管理法》《药品生产监督管理办法》 《药品生产质量管理规范》（2010年修订）和相关附录等有关要求。 | 主要生产品 ...

奥锐特公告称，公司收到浙江省药监局签发的《药品GMP符合性检查告知书》，2025年11月12 - 14日， 对其位于浙江天台县生产地址的806、863、802等车间及相关生产线进行检查，涉及原料药糠酸莫米 松、倍他米松，结论为符合相关要求。2024年，糠酸莫米松制剂、倍他米松制剂医院端销售额分别为 14.3亿元、0.15亿元。此次检查结果不会对业绩产生重大影响，产品销售受多因素影响，有不确定性。 ...

奥锐特（605116）(605116.SH)发布公告，近日，公司收到浙江省药品监督管理局签发的《药品GMP符 合性检查告知书》(浙2025第0267号、浙2025第0268号)，检查范围及相关车间、生产线：1.原料药(糠酸 莫米松)：806、863车间，A3生产线;2.原料药(倍他米松)：802车间，BETB生产线。 公司本次通过药品GMP符合性检查，表明公司相关生产线符合GMP要求，将有利于公司继续保持稳定 的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。本次获得药品GMP符合性检查结果 不会对公司业绩产生重大影响。 ...

公司本次通过药品GMP符合性检查，表明公司相关生产线符合GMP要求，将有利于公司继续保持稳定 的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。本次获得药品GMP符合性检查结果 不会对公司业绩产生重大影响。 智通财经APP讯，奥锐特(605116.SH)发布公告，近日，公司收到浙江省药品监督管理局签发的《药品 GMP符合性检查告知书》(浙2025第0267号、浙2025第0268号)，检查范围及相关车间、生产线：1.原料 药(糠酸莫米松)：806、863车间，A3生产线;2.原料药(倍他米松)：802车间，BETB生产线。 ...

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report The report presents the top ten convertible bonds for December 2025, analyzing each bond's issuer, including its financial performance, business scope, and key attractions [1][3][4]. 3. Summary by Company 3.1 Zhongte Convertible Bond - **Company Profile**: A globally leading specialized special steel material manufacturing enterprise with a production capacity of about 20 million tons of special steel materials per year [11]. - **Financial Performance**: In 2024, its operating income was 109.203 billion yuan (YoY -4.22%), and the net profit attributable to the parent was 5.126 billion yuan (YoY -10.41%). In the first three quarters of 2025, the operating income was 81.206 billion yuan (YoY -2.75%), and the net profit attributable to the parent was 4.33 billion yuan (YoY +12.88%) [11]. - **Company Highlights**: It is one of the world's most comprehensive special steel enterprises in terms of variety and specifications, with leading market shares in core products such as bearing steel and automotive steel. It has a complete industrial chain and strong cost - control capabilities, and is actively seeking external expansion [12]. 3.2 Shanlu Convertible Bond - **Company Profile**: Mainly engaged in road and bridge engineering construction and maintenance, and actively expanding into other fields. It has a complete business and management system [29]. - **Financial Performance**: In 2024, its operating income was 71.348 billion yuan (YoY -2.3%), and the net profit attributable to the parent was 2.322 billion yuan (YoY +1.47%). In the first three quarters of 2025, the operating income was 41.354 billion yuan (YoY -3.11%), and the net profit attributable to the parent was 1.41 billion yuan (YoY -3.27%) [29]. - **Company Highlights**: Controlled by the Shandong Provincial State - owned Assets Supervision and Administration Commission, it has the concept of "China Special Valuation". It is expected to benefit from infrastructure construction in Shandong and the "Belt and Road" initiative [30]. 3.3 Hebang Convertible Bond - **Company Profile**: With advantages in salt mines, phosphate mines, and natural gas supply, it has completed the basic layout in the chemical, agricultural, and photovoltaic fields [44]. - **Financial Performance**: In 2024, its operating income was 8.547 billion yuan (YoY -3.13%), and the net profit attributable to the parent was 31 million yuan (YoY -97.55%). In the first three quarters of 2025, the operating income was 5.927 billion yuan (YoY -13.02%), and the net profit attributable to the parent was 93 million yuan (YoY -57.93%) [44]. - **Company Highlights**: Its phosphate mines and salt mines contribute stable profits, and the liquid methionine business has high - margin performance [45]. 3.4 Huayuan Convertible Bond - **Company Profile**: Focused on building a complete vitamin D3 upstream - downstream industrial chain, with products including cholesterol, vitamin D3, and chemical preparations [57]. - **Financial Performance**: In 2024, its operating income was 1.243 billion yuan (YoY +13.58%), and the net profit attributable to the parent was 309 million yuan (YoY +60.76%). In the first three quarters of 2025, the operating income was 936 million yuan (YoY -0.2%), and the net profit attributable to the parent was 234 million yuan (YoY -3.07%) [57]. - **Company Highlights**: It is a leader in NF - grade cholesterol and 25 - hydroxyvitamin D3 products. It is expanding its product matrix and has a layout in the pharmaceutical manufacturing field [58]. 3.5 Xingye Convertible Bond - **Company Profile**: One of the first joint - stock commercial banks approved by the State Council and the People's Bank of China, evolving into a modern financial service group [71]. - **Financial Performance**: In 2024, its operating income was 212.226 billion yuan (YoY +0.66%), and the net profit attributable to the parent was 77.205 billion yuan (YoY +0.12%). In the first three quarters of 2025, the operating income was 161.234 billion yuan (YoY -1.82%), and the net profit attributable to the parent was 63.083 billion yuan (YoY +0.12%) [71]. - **Company Highlights**: It has stable asset quality and scale growth, with a large number of corporate and retail customers [72]. 3.6 Huanxu Convertible Bond - **Company Profile**: A global leader in electronic manufacturing design, providing value - added services to brand customers [81]. - **Financial Performance**: In 2024, its operating income was 60.691 billion yuan (YoY -0.17%), and the net profit attributable to the parent was 1.652 billion yuan (YoY -15.16%). In the first three quarters of 2025, the operating income was 43.641 billion yuan (YoY -0.83%), and the net profit attributable to the parent was 1.263 billion yuan (YoY -2.6%) [81]. - **Company Highlights**: It is a leading manufacturer of smart wearable SiP modules, with advanced packaging technologies and a global production layout [82]. 3.7 Chongyin Convertible Bond - **Company Profile**: The earliest local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, listed on the Hong Kong Stock Exchange and selected for the "Leading Bank" program [94]. - **Financial Performance**: In 2024, its operating income was 13.679 billion yuan (YoY +3.54%), and the net profit attributable to the parent was 5.117 billion yuan (YoY +3.8%). In the first three quarters of 2025, the operating income was 11.74 billion yuan (YoY +10.4%), and the net profit attributable to the parent was 4.879 billion yuan (YoY +10.19%) [94]. - **Company Highlights**: Benefiting from the Chengdu - Chongqing economic circle strategy, it has stable asset - scale growth and a reasonable credit strategy [96]. 3.8 Tianye Convertible Bond - **Company Profile**: The first industrial enterprise of the Xinjiang Production and Construction Corps and a leading enterprise in the chlor - alkali chemical industry, with an integrated circular economy industrial chain [103]. - **Financial Performance**: In 2024, its operating income was 11.156 billion yuan (YoY -2.7%), and the net profit attributable to the parent was 68 million yuan (YoY +108.83%). In the first three quarters of 2025, the operating income was 7.97 billion yuan (YoY +2.2%), and the net profit attributable to the parent was 7 million yuan (YoY -28.79%) [103]. - **Company Highlights**: The cost of caustic soda production is relatively fixed, and it plans to increase the dividend frequency and has coal - mine projects in progress [106]. 3.9 Aorui Convertible Bond - **Company Profile**: A company focusing on the R & D, production, and sales of complex APIs and preparations, leading in several technical fields [119]. - **Financial Performance**: In 2024, its operating income was 1.476 billion yuan (YoY +16.89%), and the net profit attributable to the parent was 355 million yuan (YoY +22.59%). In the first three quarters of 2025, the operating income was 1.237 billion yuan (YoY +13.67%), and the net profit attributable to the parent was 354 million yuan (YoY +24.58%) [119]. - **Company Highlights**: It has an optimized distributor network, expanding preparation products, and high - quality customer resources [120]. 3.10 Yushui Convertible Bond - **Company Profile**: The largest water supply and drainage integrated enterprise in Chongqing, with a stable monopoly position in the local market [133]. - **Financial Performance**: In 2024, its operating income was 6.999 billion yuan (YoY -3.52%), and the net profit attributable to the parent was 785 million yuan (YoY -27.88%). In the first three quarters of 2025, the operating income was 5.568 billion yuan (YoY +7.21%), and the net profit attributable to the parent was 779 million yuan (YoY +7.1%) [133]. - **Company Highlights**: It has a high market share in Chongqing, is expanding externally, and has effective cost - control measures [134].

Core Points - Aorite (605116.SH) announced a share buyback program, having repurchased a total of 2.3502 million shares as of November 30, 2025, which represents 0.58% of the company's total share capital [1] - The highest price paid for the repurchased shares was 22.59 CNY per share, while the lowest price was 18.83 CNY per share [1] - The total amount spent on the share buyback was approximately 48.9994 million CNY, excluding transaction fees [1]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 | 21 日~2026 | 年 | 1 | 月 | 20 日 | | 预计回购金额 | 6,000万元~12,000万元 | | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | √用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 2,350,238股 | | | | | ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 高管持股的基本情况 奥锐特药业股份有限公司（以下简称"公司"）高管赵珍平先生于本次减持计划实施前持有公司股份 250,000股，占公司总股本的0.06%，其所持有股份来源于公司股权激励取得的股份。 ● 减持计划的实施结果情况 公司于2025年8月5日披露了《奥锐特药业股份有限公司关于部分高管减持股份计划公告》（公告编号： 2025-054），赵珍平先生因个人资金需求，拟通过集中竞价方式减持公司股份数量不超过62,500股，减 持比例为不超过公司股份总数的0.02%，减持期间为减持股份计划公告发布之日起15个交易日后的3个 月内，若减持期间公司有派发红利、送红股、转增股本、增发新股或配股等股份变动事项，拟减持数量 将进行相应调整。 公司于2025年11月25日收到高管赵珍平先生《关于证券交易计划实施完成的告知函》。截至本公告披露 日，赵珍平先生通过集中竞价方式减持公司股票62,500股，占公司总股本的0.02%，本次减持股份计划 已实施完毕。 一、减持 ...

（文章来源：证券日报） 证券日报网讯 11月26日晚间，奥锐特发布公告称，公司于2025年11月25日收到高管赵珍平先生《关于 证券交易计划实施完成的告知函》。截至本公告披露日，赵珍平先生通过集中竞价方式减持公司股票 62，500股，占公司总股本的0.02%，本次减持股份计划已实施完毕。 ...

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 高管减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 减持计划的实施结果情况 公司于 2025 年 8 月 5 日披露了《奥锐特药业股份有限公司关于部分高管减 持股份计划公告》（公告编号：2025-054），赵珍平先生因个人资金需求，拟通过 集中竞价方式减持公司股份数量不超过 62,500 股，减持比例为不超过公司股份 总数的 0.02%，减持期间为减持股份计划公告发布之日起 15 个交易日后的 3 个 月内，若减持期间公司有派发红利、送红股、转增股本、增发新股或配股等股份 变动事项，拟减持数量将进行相应调整。 公司于 2025 年 11 月 25 日收到高管赵珍平先生《关于证券交易计划实施完 成的告知函》。截至本公告披露日，赵珍平先生通过集中竞价方式减持公司股票 62,500 股，占公司总股本 ...